Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.
Title: AGA2118, a Bispecific Antibody Neutralizing Both Sclerostin and DKK1, Increased Bone Formation and Decreased Bone Resorption, Leading to a Rapid Increase in Bone Mass and Strength in an ...
In fact, a randomized trial of abiraterone plus Ra-223 led to worse OS and an increased fracture risk in men with asymptomatic mCRPC ... the PEACE-3 trial enrolled patients with mCRPC and bone ...